Eva Steiness, CEO of Serodus, has 10 years of clinical training in medicine and has also worked in the academic sphere at the University of Copenhagen. This range of experience has given her a holistic understanding of the pharmaceutical sector from both research and commercial perspectives, putting her in good stead to head up Serodus as the company continues developing innovative drugs to treat cardiovascular disease.

Since joining Serodus in 2009, Eva has helped the company gain credibility and strength in the marketplace. “One challenge has been during the early days when we had no money and only one project that we had in-licensed. We had to convince our external partners that a small group of very experienced people are actually able to manage these compounds by outsourcing and managing those research organisations.